Acute radiation skin toxicity associated with BRAF inhibitors

Title: Acute radiation skin toxicity associated with BRAF inhibitors
Creator: Pulvirenti, T.; Hong, A.; Long, G. V.; Wang, W.; Clements, A.; Forstner, D.; Suchowersky, A.; Guminski, A.; McNeil, C.; Hersey, P.; Fogarty, G.; Kefford, R.
Relation: Journal of Clinical Oncology Vol. 34, Issue 3, p. e17-e20
Publisher Link: http://dx.doi.org/10.1200/JCO.2013.49.0565
Publisher: American Society of Clinical Oncology
Resource Type: journal article
Date: 2016
Description: BRAF inhibitors, vemurafenib and dabrafenib, are the mainstay of treatmentfor BRAF-mutant metastatic melanoma. Cutaneous toxicities are themostfrequent adverse effects, particularly hyperkeratosis (6% to 51% with vemurafenib), as well as cutaneous squamous cell carcinoma and keratoacanthoma (4.3% to 31% with vemurafenib, 6% to 11% with dabrafenib).1 Photosensitivity can occur in 52% of patients treated with vemurafenib. Radiation therapy plays an important role in the treatment of patients with metastatic melanoma. In this report, we describe five patients who experienced unanticipated increased in-field skin toxicity while undergoing radiotherapy with the concomitant use of BRAF inhibitors.
Subject: vemurafenib; dabrafenib; BRAF-mutant metastatic melanoma; radiation theraphy
Identifier: http://hdl.handle.net/1959.13/1319013
Identifier: uon:23758
Identifier: ISSN:0732-183X
Language: eng

		Thumbnail	File	Description	Size	Format